SynthesisWorld journal of surgery2021
Blumgart Anastomosis After Pancreaticoduodenectomy. A Comprehensive Systematic Review, Meta-Analysis, and Meta-Regression.
Synthesis in World journal of surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- The modified Blumgart anastomosis is associated with a lower incidence of clinically relevant postoperative pancreatic fistula and a shorter anastomotic time: a prospective cohort study with a historical control group.Surgery in practice and science · 2026Article
- Comparison of epidural anesthesia and intravenous self-control analgesia on postoperative recovery quality in duodenectomy.World journal of gastrointestinal surgery · 2026Article
- Trends in the Outcomes of Advanced Hepatobiliary-Pancreatic Surgery: The Impact of a Nationwide Clinical Database and Surgeon Certification System.Journal of hepato-biliary-pancreatic sciences · 2025Article
- A Step-By-Step Guide for Robotic Blumgart Pancreaticojejunostomy.Journal of clinical medicine · 2025Article
- Novel modified blumgart anastomosis reduces clinically relevant pancreatic fistula after pancreaticoduodenectomy: a retrospective study using inverse probability of treatment weighting.Frontiers in surgery · 2025Article
- Radiological classification of the Heidelberg triangle and its application in laparoscopic pancreaticoduodenectomy for malignancies.World journal of surgical oncology · 2024Article
- Reproduction of modified Blumgart pancreaticojejunostomy in a robotic environment: a simple clipless technique.Surgical endoscopy · 2022Article
- Algorithm-based care for early recognition and management of complications after pancreatic resection: toward standardization of postoperative care.Hepatobiliary surgery and nutrition · 2022Article
- Pancreaticojejunostomy Conducive to Biological Healing in Minimally Invasive Pancreaticoduodenectomy.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2022Review
- Redo pancreaticojejunal anastomosis for late-onset complete pancreaticocutaneous fistula after pancreaticojejunostomy.World journal of surgical oncology · 2022Article
- Pancreatic cancer in 2021: What you need to know to win.World journal of gastroenterology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe superiority of Blumgart anastomosis (BA) over non-BA duct to mucosa (non-BA DtoM) still remains under debate.
methodsWe performed a systematic search of studies comparing BA to non-BA DtoM. The primary endpoint was CR-POPF. Postoperative morbidity and mortality, post-pancreatectomy hemorrhage (PPH), delayed gastric emptying (DGE), reoperation rate, and length of stay (LOS) were evaluated as secondary endpoints. The meta-analysis was carried out using random effect. The results were reported as odds ratio (OR), risk difference (RD), weighted mean difference (WMD), and number needed to treat (NNT).
resultsTwelve papers involving 2368 patients: 1075 BA and 1193 non-BA DtoM were included. Regarding the primary endpoint, BA was superior to non-BA DtoM (RD = 0.10; 95% CI: -0.16 to -0.04; NNT = 9). The multivariate ORs' meta-analysis confirmed BA's protective role (OR 0.26; 95% CI: 0.09 to 0.79). BA was superior to DtoM regarding overall morbidity (RD = -0.10; 95% CI: -0.18 to -0.02; NNT = 25), PPH (RD = -0.03; 95% CI -0.06 to -0.01; NNT = 33), and LOS (- 4.2 days; -7.1 to -1.2 95% CI).
conclusionBA seems to be superior to non-BA DtoM in avoiding CR-POPF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.